Lead Sponsor

Eli Lilly and Company

Collaborators

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

•Are hospitalized or in the process of being admitted to hospital and have an initial laboratory determination of current COVID-19 infection less than or equal to (≤)72 hours prior to randomization
•Are men or non-pregnant women
•Women of childbearing potential must agree to use at least one highly effective form of contraception for the entirety of the study
•Agree to the collection of nasopharyngeal swabs and venous blood

•Require mechanical ventilation or anticipated impending need for mechanical ventilation
•Received convalescent COVID-19 plasma treatment prior to enrollment
•Were resident in a nursing home or long-term care facility immediately prior to current hospitalization
•Suspected or proven serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking investigational product
•Have an oxygen saturation (SpO2) less than (\<)88 percent (%) while breathing room air at rest at randomization.

Related studies

NCT06631287 · Long COVID, Sars-CoV-2 Infection, and more

NCT05101213 · Adenovirus Infection, BK Virus Infection, and more

NCT04565665 · COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome, and more

NCT06871293 · Long COVID-19 Syndrome, COVID 19, and more

NCT04978571 · Post-Concussion Syndrome, COVID Long-Haul, and more

A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19